The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Context Therapeutics Inc shares valued at $70,080 were purchased by Lehr Martin A. on Jun 09 ’25. At $0.70 per share, Lehr Martin A. acquired 100,000 shares. The insider’s holdings grew to 920,190 shares worth approximately $0.92 million following the completion of this transaction.
Also, Levit Alex C. purchased 20,000 shares, netting a total of over 11,520 in proceeds. Following the buying of shares at $0.58 each, the insider now holds 29,000 shares.
Before that, Minai-Azary Jennifer Lynn had added 40,010 shares to its account. In a trade valued at $25,486, the Chief Financial Officer bought Context Therapeutics Inc shares for $0.64 each. Upon closing the transaction, the insider’s holdings increased to 40,010 shares, worth approximately $80010.0.
As published in their initiating research note from Guggenheim on September 18, 2025, Context Therapeutics Inc [CNTX] has been a Buy and the price target has been revised to $5. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of January 08, 2025, JMP Securities has initiated its “Mkt outperform” rating for CNTX. Earlier on November 25, 2024, D. Boral Capital initiated its rating. Their recommendation was “a Buy” for CNTX stock.
Analyzing CNTX Stock Performance
On last trading session, Context Therapeutics Inc [NASDAQ: CNTX] rose 14.29% to $1.0. The stock’s lowest price that day was $0.8705, but it reached a high of $1.01 in the same session. During the last five days, there has been a surge of approximately 19.62%. Over the course of the year, Context Therapeutics Inc shares have dropped approximately -51.92%.
Is Context Therapeutics Inc subject to short interest?
Stocks of Context Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.69 million shares to 0.52 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 1.21 million shares. A decline of -131.77% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.11 of the overall float, the days-to-cover ratio (short ratio) decline to 3.11.
Which companies own the most shares of Context Therapeutics Inc (CNTX)?
In terms of Context Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5.25 in the next 12 months, up nearly 496.59% from the previous closing price of $0.88. Analysts anticipate Context Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 4.5. In spite of this, 2 analysts ranked Context Therapeutics Inc stock as Buy at the end of 2025. On May 16, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $4.50.
